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Abstract
Background
Calls for primary care providers (PCPs) to offer obese patients behavioral weight-loss 
counseling have not been accompanied by adequate guidance on how such care could 
be delivered. This randomized trial compared weight loss during a 2-year period in 
response to three lifestyle interventions, all delivered by PCPs in collaboration with 
auxiliary health professionals (lifestyle coaches) in their practices.
Methods
We randomly assigned 390 obese adults in six primary care practices to one of three 
types of intervention: usual care, consisting of quarterly PCP visits that included edu-
cation about weight management; brief lifestyle counseling, consisting of quarterly 
PCP visits combined with brief monthly sessions with lifestyle coaches who instruct-
ed participants about behavioral weight control; or enhanced brief lifestyle counseling, 
which provided the same care as described for the previous intervention but included 
meal replacements or weight-loss medication (orlistat or sibutramine), chosen by the 
participants in consultation with the PCPs, to potentially increase weight loss.
Results
Of the 390 participants, 86% completed the 2-year trial, at which time, the mean (±SE) 
weight loss with usual care, brief lifestyle counseling, and enhanced brief lifestyle 
counseling was 1.7±0.7, 2.9±0.7, and 4.6±0.7 kg, respectively. Initial weight decreased 
at least 5% in 21.5%, 26.0%, and 34.9% of the participants in the three groups, respec-
tively. Enhanced lifestyle counseling was superior to usual care on both these measures 
of success (P = 0.003 and P = 0.02, respectively), with no other significant differences 
among the groups. The benefits of enhanced lifestyle counseling remained even after 
participants given sibutramine were excluded from the analyses. There were no sig-
nificant differences between the intervention groups in the occurrence of serious 
adverse events.
Conclusions
Enhanced weight-loss counseling helps about one third of obese patients achieve long-
term, clinically meaningful weight loss. (Funded by the National Heart, Lung, and 
Blood Institute; POWER-UP ClinicalTrials.gov number, NCT00826774.)
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Investigators are searching for new approaches to the treatment of obesity during routine medical visits.1-4 Trials in which prima-
ry care providers (PCPs) offer counseling about diet 
and activity (i.e., lifestyle counseling) have led to 
weight loss of 2.5 kg or less over study periods 
ranging from 6 to 18 months.5-7 Limited treatment 
contact is probably responsible for this modest de-
gree of weight loss.1 Given the demands on pro-
viders’ time, an increase in the frequency of PCP 
counseling does not appear to be feasible.8 As an 
alternative, Tsai et al.9 trained medical assistants 
to deliver individual lifestyle counseling with the 
use of an abbreviated version of the Diabetes Pre-
vention Program.10 Overweight patients who re-
ceived eight brief counseling sessions (and met 
quarterly with their PCP to manage coexisting ill-
nesses) lost 4.4 kg in 6 months, as compared with 
0.9 kg for the patients in the control group, who 
were limited to quarterly PCP visits.
The present study expanded on this pilot inves-
tigation by assessing brief lifestyle counseling de-
livered monthly (primarily by medical assistants) in 
a 2-year, randomized trial conducted in the pri-
mary care setting. In addition to comparing the 
effectiveness of lifestyle counseling versus usual 
care, the study included a third intervention that 
was designed to increase weight loss by enhancing 
lifestyle modification with liquid meal replace-
ments or with weight-loss medication, as sug-
gested by a treatment algorithm.11 Both orlistat 
(GlaxoSmithKline) and sibutramine (Abbott) in-
crease weight loss by approximately 3 to 5 kg, as 
compared with placebo,12-14 and the same is true 
for the addition of meal replacements to lifestyle 
modification.15,16 The primary aim of the study 
was to show that both brief and enhanced brief 
lifestyle counseling would result in significantly 
greater weight loss at 24 months than would usual 
care. Secondary aims included comparing the ef-
fectiveness of the two lifestyle interventions. (Our 
study began in September 2006; in October 2010, 
sibutramine was removed from the market17 be-
cause of reports of an increase in cardiovascular 
events among patients with preexisting cardio-
vascular disease.18,19)
Methods
Study Design
The Practice-based Opportunities for Weight Re-
duction trial at the University of Pennsylvania 
(POWER-UP) was one of three trials funded by the 
National Heart, Lung, and Blood Institute to as-
sess behavioral interventions for weight loss in 
primary care practice.20 The trial was approved 
by the university’s institutional review board, and 
all participants provided written informed con-
sent. Randomization began on January 9, 2008, 
and final outcome assessments were completed on 
February 11, 2011.
Participants were recruited and treated at six 
primary care practices owned by Penn Medicine. 
Six sites were selected from a total of 27 on the 
basis of providing care to 2000 or more adults and 
having at least two physicians and two auxiliary 
health providers on staff. The sites (three urban 
and three suburban) served a racially and eco-
nomically diverse population.
The study design was proposed by six of the 
authors and was finalized in collaboration with 
members of the study steering committee.20 Data 
were gathered by one of the authors in collabora-
tion with research coordinators and were analyzed 
by two of the authors. The lead author wrote the 
first draft of the manuscript, with subsequent in-
put from all the authors, and vouches for the com-
pleteness and accuracy of the data and analyses.
Study Participants
Eligibility criteria included an age of 21 years or 
older, a body-mass index (BMI, the weight in kilo-
grams divided by the square of the height in me-
ters) of 30 to 50, and at least two of five compo-
nents of the metabolic syndrome to increase the 
likelihood that the participants would have cardio-
vascular risk factors.21 (These criteria are described 
in detail in the study protocol, available with the 
full text of this article at NEJM.org.) Exclusion cri-
teria were recent cardiovascular disease, other med-
ical conditions contraindicating weight loss, blood 
pressure of 160/100 mm Hg or higher, medications 
that substantially affect body weight (e.g., glucocor-
ticoids), substance abuse, severe psychiatric illness 
that could have affected adherence to the study, 
bariatric surgery, loss of 5% or more of initial body 
weight in the previous 6 months, and pregnancy or 
lactation.20 Antidepressant medications were per-
mitted except for those associated with marked 
weight gain (e.g., lithium). The study was conduct-
ed according to the protocol.
Screening and Randomization
Participants were recruited with the use of mul-
tiple methods, including PCP referral and self-
referral in response to in-clinic advertisements. 
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Applicants completed two on-site screening visits 
to provide informed consent and to be assessed 
by means of standardized measures of height, 
weight, and cardiovascular risk factors. Participants 
were randomly assigned to interventions (in equal 
numbers) with the use of a computer-generated 
algorithm that was operated by the Investigational 
Drug Service at the University of Pennsylvania. As-
signments were stratified by clinic, with randomly 
varied block sizes (3, 6, or 9).
Interventions
All participants were prescribed the same goals 
with respect to diet and physical activity but were 
provided with different levels of support to achieve 
them (as described in the Supplementary Appendix, 
available at NEJM.org, and the study protocol). Par-
ticipants whose weight was less than 113.4 kg were 
prescribed a balanced diet of 1200 to 1500 kcal per 
day (1500 to 1800 kcal per day for participants who 
weighed 113.4 kg or more), which consisted of 
approximately 15 to 20% kcal from protein, 20 to 
35% kcal from fat, and the remainder from carbo-
hydrate. All participants were instructed to grad-
ually increase their physical activity to 180 minutes 
per week and were given a pedometer, a calorie-
counting book,22 and handouts from Aim for a 
Healthy Weight.23
Usual Care
Participants assigned to usual care were scheduled 
for quarterly PCP visits during the 24 months of 
the study to address coexisting illnesses. At each 
visit, the PCP spent approximately 5 to 7 minutes 
reviewing the participant’s weight change and 
discussing the information provided in the hand-
outs.23 The PCPs followed written protocols and 
were instructed not to provide specific behavioral 
strategies for changing eating and activity habits.
Brief Lifestyle Counseling
Participants assigned to brief lifestyle counseling 
were scheduled for the same quarterly PCP visits 
as the usual-care group but also spent 10 to 15 
minutes each month with an auxiliary health care 
provider (medical assistant), referred to as a lifestyle 
coach, who delivered treatment by following abbre-
viated lessons from the Diabetes Prevention Pro-
gram.9,10,24 Visits began with a weigh-in and then a 
review of participants’ recording of food intake, 
physical activity, and other goals prescribed in se-
quential monthly handouts (as listed in the Supple-
mentary Appendix). For month 1 only, participants 
had two counseling visits to instruct them about 
how to record food and calorie intake in diaries 
provided. In year 2, they were permitted, every 
other month, to complete counseling visits by 
telephone (although <5% of visits were made by 
telephone).
Enhanced Brief Lifestyle Counseling
Participants assigned to enhanced lifestyle coun-
seling had the same PCP and counseling visits as 
those assigned to brief lifestyle counseling. How-
ever, in consultation with their PCP, they also chose 
to take sibutramine, orlistat, or meal replacements 
to increase weight loss, beginning 1 month after 
treatment began. (Participants were allowed to 
choose among these options in order to make the 
additional treatment acceptable to them and also 
to reflect the way such interventions are most likely 
be selected in the primary care setting.) Sibutra-
mine was provided at a dose of 10 mg per day, with 
the option of increasing the dose to 15 mg per day 
after 6 months if blood pressure and pulse mea-
surements were within acceptable ranges.25 Orlistat 
was provided at a dose of 60 mg per meal,26 with 
the option of increasing the dose to 120 mg after 
6 months. Participants who chose meal replace-
ments were instructed to replace two meals and 
one snack each day with shakes or meal bars 
(Slim-Fast, Unilever) for the first 4 months and 
to replace one meal and one snack each day for 
the remainder of the study.27 (Both orlistat and the 
meal-replacement products were donated by the 
respective manufacturers, which had no role in 
the design of the study, data collection and analy-
sis, or preparation of the manuscript.) Participants 
were allowed only one enhancement at a time (i.e., 
medication or meal replacements, all of which were 
provided without charge) but could switch be-
tween them with the approval of their PCP. After 
sibutramine was removed from the market, par-
ticipants who took this medication switched to 
either meal replacements or orlistat. (This option 
was also offered in November 2009 after the Food 
and Drug Administration [FDA] issued an alert 
concerning the safety of sibutramine.)
PCPs  and Lifestyle Coaches
Thirty of 31 PCPs across the six sites participated 
as study providers; only 1 had considerable weight-
management experience. Two or three lifestyle 
coaches were identified at each site on the basis of 
their good rapport with patients; none had experi-
ence with weight management, and none had to 
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meet a body-mass index requirement to serve as a 
coach. Delivery of the interventions was standard-
ized across sites with the use of detailed protocols. 
The year before the intervention began, study staff 
provided 6 to 8 hours of training to PCPs and life-
style coaches. All providers were certified in inter-
vention delivery at baseline and were recertified 
at 6-month intervals, according to previously de-
scribed methods.27 Throughout the trial, the study 
staff met with PCPs and coaches (for 30 to 60 min-
utes) approximately quarterly and monthly, respec-
tively, to review protocol implementation.
Outcomes and Assessments
The primary outcome was the change in body 
weight at month 24 in each of the lifestyle-counsel-
ing groups as compared with the usual-care group. 
Secondary outcomes included weight change in the 
enhanced-lifestyle-counseling group as compared 
with weight change in the lifestyle-counseling 
group and the percentages of participants in each 
of the three groups whose initial weight was de-
creased by 5% or more at 12 and 24 months and by 
10% or more at 12 and 24 months. Weight was 
measured by a certified staff member at baseline 
and at 6, 12, 18, and 24 months with the use of a 
digital scale (Tanita BWB-800). Waist circumfer-
ence, blood pressure, and fasting levels of blood 
glucose, triglycerides, and cholesterol (total, high-
density lipoprotein [HDL], and low-density lipo-
protein [LDL]) were assessed at baseline and at 
months 6, 12, and 24 with the use of standard-
ized methods described previously25 (and in the 
protocol).
Statistical Analysis
Changes in weight in the intention-to-treat 
population were compared with the use of repeated-
measures linear mixed-effects models (for continu-
ous outcomes) and generalized-estimating-equa-
tion models (for categorical outcomes), which 
controlled for initial weight, age, sex, race or ethnic 
group, and study site. The study had 80% power 
to detect a 2.75-kg difference in weight change at 
month 24 between the usual-care and brief-life-
style-counseling groups and between the usual-
care and enhanced-lifestyle-counseling groups. 
Holm’s procedure28 was used to adjust for multi-
ple comparisons and to identify significant dif-
ferences in at least one of the two between-group 
comparisons (P = 0.025). For analyses of secondary 
outcomes, a P value of 0.05 or less was considered 
to indicate statistical significance.
Results
Baseline Characteristics of the Study 
Participants
The participants included 311 women (79.7%) and 
79 men with a mean (±SD) age of 51.5±11.5 years, 
a mean body weight of 107.7±18.3 kg, and a mean 
BMI of 38.5±4.7 (Table 1). Nearly 95% had com-
pleted high school or above; 59.0% identified 
themselves as white, 38.5% as black, and 4.6% as 
Hispanic. Participants who received enhanced life-
style counseling weighed significantly less than 
those who received usual care (P = 0.02), a differ-
ence addressed in the analyses by the a priori deci-
sion to control for initial weight.
Approximately 86% of the participants in each 
group had their weight measured at 24 months 
(Fig. 1). Reasons for missed visits at the 24-month 
assessment included withdrawal from the study 
(3 participants), censoring of data because of 
pregnancy (1 participant) and bariatric surgery 
(1 participant), and loss to follow-up (49 partici-
pants).
Weight Loss
Intention-to-Treat Population
At month 24, the mean (±SE) weight loss among 
participants assigned to usual care, those assigned 
to brief lifestyle counseling, and those assigned to 
enhanced lifestyle counseling was 1.7±0.7, 2.9±0.7, 
and 4.6±0.7 kg, respectively. Enhanced lifestyle 
counseling resulted in significantly greater weight 
loss than did usual care (Table 2), whereas other 
between-group differences were not significant. 
(Sensitivity analyses, in which multiple imputation 
was used to assess the effects of missing data, 
yielded similar results.) Weight losses in all three 
groups differed significantly from one another at 
month 6, and the maximum weight loss was gen-
erally reached at month 12 (Table 2). The percent 
reduction in initial weight is shown in Figure 2 
and Table 2; changes in the BMI are also shown 
in Table 2.
At baseline, participants who received enhanced 
lifestyle counseling chose one of three additional 
treatment enhancements: meal replacements 
(67 participants), sibutramine (38), or orlistat (24). 
An intention-to-treat analysis, based on partici-
The New England Journal of Medicine 
Downloaded from nejm.org on March 27, 2015. For personal use only. No other uses without permission. 
 Copyright © 2011 Massachusetts Medical Society. All rights reserved. 
Obesity Treatment in Primary Care Practice
n engl j med 365;21 nejm.org november 24, 2011 1973
Table 1. Baseline Characteristics of the Participants.*
Characteristic
Usual Care
(N = 130)
Brief Lifestyle 
Counseling
(N = 131)
Enhanced Brief 
Lifestyle Counseling
(N = 129)
Total
(N = 390)
Sex — no. of patients (%)
Female 98 (75.4) 110 (84.0) 103 (79.8) 311 (79.7)
Male 32 (24.6) 21 (16.0) 26 (20.2) 79 (20.3)
Race or ethnic group — no. of patients (%)†
White 81 (62.3) 75 (57.3) 74 (57.4) 230 (59.0)
Black 46 (35.4) 52 (39.7) 52 (40.3) 150 (38.5)
Asian 2 (1.5) 0 2 (1.6) 4 (1.0)
More than one race 1 (0.8) 4 (3.1) 1 (0.8) 6 (1.5)
Self-reported Hispanic
Yes 6 (4.6) 6 (4.6) 6 (4.7) 18 (4.6)
No 124 (95.4) 125 (95.4) 123 (95.3) 372 (95.4)
Education — no. of patients (%)
Less than high school 10 (7.7) 5 (3.8) 6 (4.7) 21 (5.4)
High school 25 (19.2) 27 (20.6) 26 (20.2) 78 (20.0)
Some college or associate’s degree 43 (33.1) 50 (38.2) 48 (37.2) 141 (36.2)
Bachelor’s degree 29 (22.3) 26 (19.8) 27 (20.9) 82 (21.0)
Graduate or professional degree 23 (17.7) 23 (17.6) 22 (17.1) 68 (17.4)
Age — yr 51.7±12.1 52.0±12.2 51.0±10.1 51.5±11.5
Weight — kg‡ 111.2±20.0 106.3±17.3 105.4±17.2 107.7±18.3
Height — cm 168.5±8.7 165.9±8.6 166.9±8.6 167.1±8.7
Body-mass index§ 39.0±4.8 38.5±4.6 37.8±4.7 38.5±4.7
Waist circumference — cm‡ 119.8±13.9 117.1±11.9 115.9±11.7 117.6±12.6
Triglycerides — mg/dl 120.5±58.9 120.7±69.5 111.5±59.4 117.5±62.7
Cholesterol — mg/dl
Low-density lipoprotein 112.1±38.7 116.0±31.0 118.1±31.3 115.4±33.8
High-density lipoprotein 44.0±12.7 45.4±12.9 48.6±14.9 46.0±13.6
Total 181.7±46.8 185.5±35.9 189.1±35.5 185.5±39.7
Fasting glucose — mg/dl‡ 112.3±40.1 106.2±32.2 96.3±22.5 104.9±32.9
Blood pressure — mm Hg
Systolic 120.9±18.4 122.8±15.6 120.5±14.7 121.4±16.3
Diastolic 76.0±10.4 75.9±11.3 76.5±9.7 76.2±10.4
Medical conditions — no. of patients (%)
Hypertension 92 (70.8) 93 (71.0) 92 (71.3) 277 (71.0)
Diabetes mellitus 29 (22.3) 26 (19.8) 16 (12.4) 71 (18.2)
Hypercholesterolemia 78 (60.0) 93 (71.0) 82 (63.6) 253 (64.9)
* Plus–minus values are means ±SD. P>0.05 for all comparisons except as otherwise noted. To convert the values for tri-
glycerides to millimoles per liter, multiply by 0.01129. To convert the values for cholesterol to millimoles per liter, mul-
tiply by 0.02586. To convert the values for glucose to millimoles per liter, multiply by 0.05551.
† Race and Hispanic ethnic group were self-reported.
‡ P<0.05 for the comparison between the usual-care group and the enhanced-lifestyle-counseling group.
§ The body-mass index is the weight in kilograms divided by the square of the height in meters.
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390 Underwent randomization
528 Underwent in-person screening
1196 Participants were prescreened for eligibility
650 Were excluded
18 Withdrew
104 Were excluded
37 Did not meet criteria for metabolic syndrome 
15 Had medical or psychiatric reason
10 Had BMI >50
5 Had BMI <30
6 Lost ≥5% of body weight
3 Were taking medication
23 Did not have time
5 Had other reasons
34 Were eligible but withdrew
130 Were assigned to usual care
129 Were assigned to enhanced
brief lifestyle counseling
112 Had weight measured
at 6-mo assessment
118 Had weight measured
at 6-mo assessment
131 Were assigned to brief
lifestyle counseling
109 Had weight measured
at 6-mo assessment
109 Had weight measured
at 12-mo assessment
105 Had weight measured
at 18-mo assessment
110 Had weight measured at 24-mo
assessment
20 Missed visit
19 Were lost to follow-up
1 Withdrew from study
130 Were included in primary analysis
112 Had weight measured
at 12-mo assessment
98 Had weight measured
at 18-mo assessment
111 Had weight measured
at 12-mo assessment
101 Had weight measured
at 18-mo assessment
112 Had weight measured at 24-mo
assessment
19 Missed visit
16 Were lost to follow-up
2 Withdrew from study
1 Underwent bariatric surgery
(data censored)
131 Were included in primary analysis
114 Had weight measured at 24-mo
assessment
15 Missed visit
14 Were lost to follow-up
1 Was pregnant (data censored)
129 Were included in primary analysis
Figure 1. Screening, Randomization, and Assessments of Study Participants.
Of the 129 participants randomly assigned to enhanced brief lifestyle counseling, 67, 38, and 24 initially chose to use 
meal replacements, sibutramine, and orlistat, respectively. BMI denotes body-mass index (the weight in kilograms 
divided by the square of the height in meters).
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pants’ initial choice of enhancement, revealed a 
mean weight loss of 3.9±1.0, 5.5±1.3, and 4.6±1.7 
kg in these three subgroups, respectively, at month 
24, with no significant differences among them. 
Eleven participants (16%) who initially chose meal 
replacements switched to a different enhancement, 
as did 15 participants (39%) who chose sibutra-
mine (including 9 in whom the drug was with-
drawn in response to the FDA’s actions) and 
8 participants (33%) who chose orlistat. For all the 
sibutramine-treated participants, the assessment 
at month 6 preceded the withdrawal of the medi-
cation from the market. Weight losses at this time 
point and the results of other assessments can be 
found in Figure 1 in the Supplementary Appendix.
Modified Intention-to-Treat Population
Weight loss at month 24 among the 129 partici-
pants who received enhanced lifestyle counseling 
was reanalyzed, excluding the 44 participants who 
received sibutramine at any time. The remain-
ing 85 participants lost a mean of 4.3±0.8 kg at 
month 24, which was significantly greater than the 
loss for those who received usual care (1.7±0.7 kg) 
but did not differ significantly from the weight 
loss for those who received brief lifestyle counsel-
ing (2.9±0.7 kg). Table 1 in the Supplementary Ap-
pendix shows weight loss in this modified inten-
tion-to-treat population. An analysis of weight loss 
in the 66 participants in the enhanced-lifestyle-
counseling group who used meal replacements 
(without exposure to sibutramine) for most of the 
trial revealed a loss of 4.1±0.9 kg at month 24, 
which was significantly greater than that in the 
usual-care group (P = 0.04) but did not differ sig-
nificantly from the weight loss in the brief-life-
style-counseling group (P = 0.30).
Categorical Weight Loss
Figure 3 shows categorical weight loss in the 
intention-to-treat population: the percentages of 
participants in the three groups whose weight 
was at or below their baseline weight at months 
12 and 24, the percentages of participants who had 
Table 2. Estimated Mean Weight Loss, Percent Reduction in Body Weight, and Change in Body-Mass Index over a 24-Month Period 
in the Intention-to-Treat Population.*
Variable
Usual Care 
(N = 130)
Brief LC 
(N = 131)
Enhanced Brief LC 
(N = 129) P Value
Brief LC  
vs. Usual Care
Enhanced Brief LC 
vs. Usual Care
Enhanced Brief LC 
vs. Brief LC
Change in body weight (kg)
At month 6 −2.0±0.5 −3.5±0.5 −6.6±0.5 0.03 <0.001 <0.001
At month 12 −2.3±0.6 −3.4±0.6 −7.1±0.6 0.23 <0.001 <0.001
At month 18 −1.9±0.7 −3.0±0.7 −5.8±0.7 0.22 <0.001 0.004
At month 24 −1.7±0.7 −2.9±0.7 −4.6±0.7 0.22 0.003 0.08
Change in weight (%)
At month 6 −1.8±0.5 −3.5±0.5 −6.5±0.5 0.005 <0.001 <0.001
At month 12 −2.1±0.6 −3.5±0.6 −7.0±0.6 0.08 <0.001 <0.001
At month 18 −1.7±0.7 −3.1±0.7 −5.8±0.6 0.10 <0.001 0.002
At month 24 −1.6±0.6 −2.9±0.7 −4.7±0.6 0.12 <0.001 0.04
Change in body-mass index†
At month 6 −0.7±0.2 −1.3±0.2 −2.4±0.2 0.02 <0.001 <0.001
At month 12 −0.8±0.2 −1.3±0.2 −2.5±0.2 0.18 <0.001 <0.001
At month 18 −0.7±0.2 −1.1±0.2 −2.1±0.2 0.17 <0.001 0.005
At month 24 −0.6±0.2 −0.9±0.2 −1.6±0.2 0.27 0.003 0.05
* Plus–minus values are means ±SE. The data for the three intervention groups are model-based estimates for the intention-to-treat population. 
The numbers of participants for whom weight measurements were available at 6, 12, 18, and 24 months were as follows: for the group that re-
ceived usual care, 112, 109, 105, and 110 participants, respectively; for the group that received brief lifestyle counseling (LC), 109, 112, 98, and 
112 participants, respectively; and for the group that received enhanced brief LC, 118, 111, 101, and 114 participants, respectively.
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lost 5% or more of their initial weight at months 
12 and 24, and the percentages of participants 
who had lost 10% or more of their initial weight 
at months 12 and 24. All categorical weight losses 
at 12 and 24 months were significantly greater in 
the group that received enhanced lifestyle coun-
seling than in the group that received usual care. 
(Fig. 2 in the Supplementary Appendix shows the 
results for the modified intention-to-treat popu-
lation.)
Attendance at Scheduled Visits
Participants in the usual-care, lifestyle-counseling, 
and enhanced-lifestyle-counseling groups attend-
ed 71.8±28.6%, 69.0±29.1%, and 76.7±27.4% of the 
8 scheduled PCP visits, respectively. The frequency 
of attendance (across groups) declined from year 
1 (81.7±24.9%) to year 2 (61.0±39.2%) (P<0.001). 
Participants in the lifestyle-counseling group and 
those in the enhanced-lifestyle-counseling group 
attended 56.1±28.8% and 64.7±25.8% of the 25 
scheduled coaching visits, respectively. Attendance 
was higher in the enhanced-lifestyle-counseling 
group than in the lifestyle-counseling group 
(P = 0.01) and declined across both groups from 
year 1 (72.1±25.4%) to year 2 (45.6±35.2%) 
(P<0.001). Figure 3 in the Supplementary Appen-
dix shows that for each intervention group, higher 
attendance generally was associated with greater 
weight loss.
Changes in Cardiovascular Risk Factors
Participants who received enhanced lifestyle coun-
seling had significantly greater improvements in 
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Panel A shows the percentage of participants in each 
group in the intention-to-treat population who were at 
or below their baseline weight at months 12 and 24. 
(Participants for whom data on weight were missing 
were assumed to have a weight above the baseline 
weight.) Panel B shows the percentage of participants 
who lost 5% or more of their baseline weight, and Pan-
el C shows the percentage of participants who lost 
10% or more of their baseline weight. (The percentage 
of participants who lost 5% or more of their baseline 
weight includes the percentage who lost 10% or more.)
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waist circumference and in HDL cholesterol and 
triglyceride levels at one or more assessments, as 
compared with the other two groups (in the inten-
tion-to-treat population) (Table 2A in the Supple-
mentary Appendix). However, this group had sig-
nificantly smaller reductions in LDL cholesterol 
levels at month 24. Blood pressure was essentially 
unchanged from normal baseline values.
Adverse Events
A total of 73 hospitalizations for serious adverse 
events were reported by participants during the 
2-year trial. This included 21 events in 16 partici-
pants in the usual-care group, 26 events in 20 par-
ticipants in the brief-lifestyle-counseling group, 
and 26 events in 22 participants in the enhanced-
lifestyle-counseling group, with no significant 
differences between groups (P = 0.556). There were 
no deaths. (See Table 3 in the Supplementary Ap-
pendix for a list of all events according to inter-
vention group.) Only three events — two chole-
cystectomies and one case of syncope — were 
judged by the study physicians to be related to 
the intervention. Sibutramine was discontinued 
in five participants because of increases in blood 
pressure (≥10 mm Hg), in a sixth participant be-
cause of tachycardia, and in a seventh because of 
anxiety. Orlistat was discontinued in five partici-
pants because of gastrointestinal symptoms.
Discussion
The principal finding of this study was that PCPs, 
collaborating with medical assistants, helped one 
group of their obese patients lose an average of 
4.7% of their initial weight at 24 months. This loss, 
which was accompanied by improvements in car-
diovascular risk factors, was achieved with en-
hanced brief lifestyle counseling, which combined 
quarterly PCP visits, brief lifestyle coaching deliv-
ered monthly, and the use of meal replacements or 
weight-loss medication. Thirty-five percent of the 
participants assigned to this intervention lost 5% or 
more of their initial weight, which is a common 
criterion for clinically meaningful weight loss.11,29 
Long-term weight loss in the group that received 
enhanced lifestyle counseling (as well as in the 
group that received brief lifestyle counseling with-
out enhancement) was greater than weight loss 
observed in other primary care trials,5-7,30,31 with 
the exception of a study involving extremely obese 
patients who were treated with intensive group life-
style modification and weight-loss medications.32 
Enhanced lifestyle counseling offers a model for 
treating obesity in primary care practices with the 
help of regular staff members (PCPs and medical 
assistants).
As compared with usual care, only the en-
hanced counseling led to a significant increase in 
weight loss at month 24; brief counseling without 
enhancement did not result in the 4-kg weight loss 
expected in light of the results of the pilot study.9 
Participants who received the brief lifestyle coun-
seling attended significantly fewer coaching ses-
sions than did those who received the enhanced 
counseling, despite the fact that the same per-
sonnel delivered both interventions. In contrast, 
participants who received the usual care lost 
more than the expected 1 kg, probably because 
the weight-management support they were given 
(quarterly PCP visits, a calorie book, and a pedom-
eter) to encourage them to remain in the study was 
greater than the support that would typically be 
provided in the primary care setting. Our findings 
suggest that PCPs may be able to assist one fifth 
of their obese patients in losing 5% or more of 
body weight by providing educational materials 
and briefly discussing weight management at 
quarterly visits.
Our study shows that combining quarterly PCP 
visits with brief monthly lifestyle coaching provid-
ed by medical assistants does not significantly 
increase weight loss, as compared with PCP vis-
its alone. The use of specialized personnel (e.g., 
registered dietitians),15 as well as more intensive 
coaching (i.e., more than one session per month 
for the first 3 months), as recommended by the 
U.S. Preventive Services Task Force,1 could in-
crease weight loss.33 However, both options would 
have considerable financial and logistic conse-
quences for primary care practices, and as sug-
gested by our attendance data, participants might 
not be willing to make additional office visits.
The strengths of this study include the random-
ized design, the provision of interventions by pri-
mary care personnel who treated obese patients 
in their local practices (rather than the provision of 
interventions by specialized personnel to highly 
selected volunteer subjects), and the high rate of 
study completion by participants (86%). Limita-
tions included the provision of free treatment 
enhancements (which may limit the generaliz-
ability of the results); the need for longer follow-
up; and the withdrawal of sibutramine from the 
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market, which clouded interpretation of the find-
ings for the group of participants who received 
enhanced brief lifestyle counseling. Nonetheless, 
the beneficial effects of this latter approach re-
mained even after analyses were limited to persons 
who received only meal replacements or orlistat, 
each of which continues to be available. The study 
also confirmed the problem of weight regain de-
spite ongoing counseling for weight-loss mainte-
nance.34
Our data support the screening by PCPs of all 
adults for obesity, as well as efforts to help 
patients understand the health consequences of 
excess weight and the benefits of modest weight 
loss; these practices are consistent with prior rec-
ommendations.1,11 By providing enhanced life-
style counseling, as described here, PCPs could 
help a considerable minority of obese persons 
achieve clinically meaningful weight loss,11,29 
which they might not achieve if they were simply 
told to reduce their weight on their own. The 
treatment model used in this study awaits com-
parison with community-based approaches,24,35 as 
well as with electronically delivered interventions 
(including the Internet,36 mobile telephones,37 
and telephone counseling33,38), which could result 
in equivalent or greater weight loss. Although our 
study has shown that primary care personnel can 
provide effective weight-management support, it 
has not addressed the more challenging question 
of who will pay for these or related weight-loss 
interventions.39
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